A prospective clinical trial to assess safety and efficacy of darunavir/ritonavir (TMC 114/r), etravirine (TMC 125) and MK-0518 [raltegravir] in addition to optimized background regimen in HIV-1 infected patients with limited to no treatment options ANRS 139 TRIO.

Trial Profile

A prospective clinical trial to assess safety and efficacy of darunavir/ritonavir (TMC 114/r), etravirine (TMC 125) and MK-0518 [raltegravir] in addition to optimized background regimen in HIV-1 infected patients with limited to no treatment options ANRS 139 TRIO.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2015

At a glance

  • Drugs Etravirine (Primary) ; Raltegravir (Primary) ; Darunavir; Enfuvirtide; Nucleoside reverse transcriptase inhibitors; Ritonavir
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TRIO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Nov 2009 Status changed from active, no longer recruiting to completed, according to results reported in Clinical Infectious Diseases.
    • 01 Nov 2009 Results have been published in full in Clinical Infectious Diseases 2009; 49-1441-9.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top